HilleVax, Inc.: 5%+ holders

HilleVax, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-24. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Frazier Life Sciences Public Fund, L.P.

Item 4 of the Schedule 13D is hereby amended to incorporate the following at the end thereof: On August 4, 2025, the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 4 Corp., a wholly owned subsidiary of Purchaser ("Merger Sub") entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Purchaser commenced a tender offer (the "Offer") to acquire all of the outstanding shares of Common Stock of the Issuer (the "Shares"), at an offer price of (i) $1.95 in cash, without interest, plus (ii) one non-transferable contractual contingent value right per Share (collectively, the "Offer Price"). The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time, on September 15, 2025. On September 17, 2025, Purchaser accepted for purchase all shares of Common Stock that were validly tendered and not validly withdrawn in accordance with the terms of the Offer, which included the Shares that were held by the Reporting Persons. On September 17, 2025, upon the terms and subject to the conditions set forth in the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation Law, Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Purchaser (the "Merger"), without a meeting or vote of stockholders of the Issuer (the "Effective Time"). At the Effective Time, the Shares held by the Reporting …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-09-17; the filing has the rest

Tang Capital Management, LLC

Item 4 of the Schedule 13D is amended by adding the following: Closing of the Merger: On September 17, 2025, the Issuer completed its merger with XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 4 Corp. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on September 17, 2025, each issued and outstanding share of the Issuer's Common Stock was cancelled.Item 4 of the SCHEDULE 13D/A filed 2025-09-19

Takeda Pharmaceutical Company Limited

The cash tender offer (the "Tender Offer") by XOMA Royalty Corporation, a Nevada corporation ("Parent") and XRA 4 Corp., a Delaware corporation ("Merger Sub") and a wholly owned subsidiary of Parent, to purchase all of the outstanding shares of the Common Stock (collectively, the "Shares" and each, a "Share") at an offer price of (i) $1.95 per Share and (ii) one non- transferable contractual contingent value right ( "CVR"), expired as scheduled at one minute after 11:59 p.m., Eastern Time, on September 15, 2025 (the "Expiration Time") and closing of the Tender Offer was announced September 17, 2025. As all conditions to the Tender Offer were satisfied or waived, on September 15, 2025, Parent irrevocably accepted for payment all Shares validly tendered into and not validly withdrawn from the Tender Offer and paid for all such Shares in accordance with the Tender Offer. On September 17, 2025, following the consummation of the Tender Offer, upon the terms and conditions set forth in the Agreement and Plan of Merger, dated as of August 4, 2025, the Company filed a Certificate of Merger with the Secretary of State of the State of Delaware, pursuant to which the merger (the "Merger") became effective. In the Merger, Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation (the "Surviving Corporation"). As a result of the Merger, the Company ceased to be a publicly traded company and became a privately held company and a subsidiary …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-09-19; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes